摘要
Thrombotic complications appear to be a major predictor of death in COVID-19 patients,and multiple studies have shown that anticoagulants can help to improve the outcome.The Food and Drug Administration’s acceptance of non-vitamin K antagonist oral anticoagulants(NOACs)has sparked much excitement about their potential as a replacement for existing oral anticoagulants.NOACs target a single clotting factor,often activated factor X or thrombin,and involve the coagulation factor Xa inhibitors including apixaban,edoxaban,and rivaroxaban,and the thrombin inhibitor dabigatran.COVID-19 is an infectious disease that causes thrombotic events by inducing a pro-inflammatory and prothrombotic condition.This article provides a comprehensive overview of the mechanism behind enhanced thrombogenicity accompanying COVID-19,the clinical range of NOACs,and the role of NOACs in treatment of COVID-19 based on recent investigations and clinical trials.
